EVP-6124 Hepatic Impairment Study

Summary

The purpose of this study is to assess the pharmacokinetics of EVP-6124 and metabolites after a single oral dose in subjects with mild, moderate and severe hepatic impairment compared with subjects with normal hepatic function.

Timeline

Start

2013-06

Primary completion

2014-12

Completion

—

Drugs

Indications

No indication recorded.